Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letaplimab + Azacitidine in Higher Risk MDS
NCT04485065Phase 1Suspended
- Sponsor
- Innovent Biologics
- Start
- Sep 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of letaplimab in myelodysplastic syndrome (MDS), sponsored by Innovent Biologics. Primary endpoints: Safety and tolerability at 24 months, Complete response rate at 24 months and 1 more. Started Sep 2020; status: suspended.
02
Drugs
letaplimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04485065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485065.